4D MOLECULAR THERAPEUTICS IN shareholders Q2 2023

4D MOLECULAR THERAPEUTICS IN's ticker is FDMT and the CUSIP is 35104E100. A total of 101 filers reported holding 4D MOLECULAR THERAPEUTICS IN in Q2 2023. The put-call ratio across all filers is 1.67 and the average weighting 0.2%.

4D MOLECULAR THERAPEUTICS IN shareholders Q2 2023
NameSharesValueWeighting ↓
Sandia Investment Management LP 7,500$135,5250.03%
PROFUND ADVISORS LLC 28,779$520,0370.03%
HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND 334,300$6,040,8010.03%
Caption Management, LLC 71,900$1,299,2330.02%
Candriam S.C.A. 173,000$3,126,1100.02%
Rafferty Asset Management, LLC 197,155$3,562,5910.02%
Point72 Asset Management, L.P. 370,887$6,701,9280.02%
Verition Fund Management LLC 72,709$1,313,8520.02%
VOLORIDGE INVESTMENT MANAGEMENT, LLC 135,661$2,451,3940.01%
BRIDGEWAY CAPITAL MANAGEMENT, LLC 27,400$495,1180.01%
Bellevue Group AG 45,000$813,1500.01%
FIRST MANHATTAN CO. LLC. 144,492$2,610,9700.01%
TWO SIGMA INVESTMENTS, LP 185,139$3,345,4620.01%
DEUTSCHE BANK AG\ 676,153$12,218,0840.01%
TWO SIGMA ADVISERS, LP 112,346$2,030,0920.01%
Caption Management, LLC 11,944$215,8280.00%
Blackstone Inc. 50,000$903,5000.00%
China Universal Asset Management Co., Ltd. 549$100.00%
Cutler Group LLC / CA 1,000$180.00%
MORGAN STANLEY 1,567,759$28,329,4040.00%
External links

This page lists 4D MOLECULAR THERAPEUTICS IN's shareholders in Q2 2023. To view 4D MOLECULAR THERAPEUTICS IN's shareholder history, click here.